Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Hossein-Ardeschir Ghofrani, Gérald Simonneau, Andrea Maria D’Armini, Peter F. Fedullo, Luke Howard, Xavier Jaïs, David P. Jenkins, Zhi‐Cheng Jing, Michael M. Madani, Nicolas Martin, Eckhard Mayer, Kelly Papadakis, Dominik Richard, Nick H. Kim, Iréne Lang, Christian M. Kähler, Marion Delcroix, Zoheir Bshouty, Pablo S. Varela, Zhi‐Cheng Jing, Yuanhua Yang, Jinming Liu, Gangcheng Zhang, Nuofu Zhang, Yuhong Mi, Xianyang Zhu, Pavel Jansa, Xavier Jaïs, Grégoire Prévôt, Hélène Bouvaist, Olivier Sanchez, Friedrich Grimminger, Matthias Held, Heinrike Wilkens, Stephan Rosenkranz, Ekkehard Grünig, Kristóf Karlócai, A Temesvári, István Édes, Sigita Aidietienė, Skaidrius Miliauskas, Tomás René Pulido Zamudio, Carlos Jerjes Sánchez, Anton Vonk Noordegraaf, Jerzy Lewczuk, Piotr Podolec, Jarosław D. Kasprzak, Tatiana Mularek‐Kubzdela, Ryszard Grzywna, Keertan Dheda, О. М. Моисеева, Alexander Chernyavskiy, В. М. Шипулин, О. Л. Барбараш, T. V. Martynyuk, Hyung‐Kwan Kim, Jun‐Bean Park, Jae Seung Lee, Rudolf Speich, Silvia Ulrich, John‐David Aubert, Arintaya Phrommintikul, Nattapong Jaimchariyatam, Suree Sompradeekul, Zeynep Pınar Önen, Gülfer Okumuş, Lyubomyr Solovey, Volodymyr Gavrysyuk, Luke Howard, Joanna Pepke‐Żaba, Robin Condliffe, John McConnell, Kim M. Kerr, Lan Hieu Nguyen, Nguyen Vinh Pham